Background Thyroid-stimulating hormone (TSH) suppression is recommended for patients
who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of …

Simple Summary In order to reduce the recurrence rate after surgical treatment of
differentiated thyroid cancer (DTC), suppression of thyroid-stimulating hormone (TSH) or …

Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is
recommended for patients with intermediate-and high-risk differentiated thyroid cancer to …

Background Thyroid lobectomy is recommended as the primary treatment for low-risk thyroid
cancer. However, recurrence and hypothyroidism may develop after lobectomy …

Background: This study was undertaken to determine the optimal thyroid‐stimulating
hormone (TSH) value associated with structural recurrence in patients with low‐risk or …

Context: TSH suppression therapy has been used to decrease thyroid cancer recurrence.
However, validation of effects through studies providing a high level of evidence has been …

Background: This study aimed to identify the clinical results after thyrotropin suppression
therapy (TST) cessation and evaluated clinical factors associated with successful TST …

Objective To determine the frequency of levothyroxine (LT4) supplementation after
therapeutic lobectomy for low-risk differentiated thyroid cancer (DTC). Methods This …

Background Thyrotropin (TSH) suppression is a critical step in the management of
differentiated thyroid carcinoma (DTC). The objectives of this study were to evaluate …

Background: Lobectomy with preservation of the contralateral lobe has already become the
most preferred surgical method for patients with low-risk thyroid cancer. The incidence of …